Yahoo
    HKSE - Delayed Quote HKD

    Akeso, Inc. (9926.HK)

    78.900 -2.600 (-3.19%)
    At close: 4:08:14 PM GMT+8
    Loading Chart for 9926.HK
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    View More
    Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

    Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab
    PR Newswire 14d ago
    Is Akeso (SEHK:9926) A Bargain Following Its New Phase III Colon Cancer Trial?

    Is Akeso (SEHK:9926) A Bargain Following Its New Phase III Colon Cancer Trial?
    Simply Wall St. 22d ago
    First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer

    First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
    PR Newswire 23d ago
    Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026

    Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
    PR Newswire 1mo ago
    Akeso (SEHK:9926) Stock Still Looks Cheap Despite Its 141% Run

    Akeso (SEHK:9926) Stock Still Looks Cheap Despite Its 141% Run
    Simply Wall St. 1mo ago
    Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China

    Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
    Business Wire 1mo ago
    Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC

    Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
    PR Newswire 1mo ago
    Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

    Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
    PR Newswire 2mo ago
    SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

    SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
    Zacks 2mo ago
    Akeso logs Phase III success in second tumour type for ivonescimab

    Akeso logs Phase III success in second tumour type for ivonescimab
    Clinical Trials Arena 2mo ago
    Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

    Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
    Business Wire 2mo ago
    View More

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: